Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events

BMC Cancer

Table 1 Genes regulated by BCR-ABL.

A. Microarray Analysis
Genes Regulated by BCR-ABL
	Fold-Change	Gene Name
Induced Genes	13.00	Complement component 3 (C3)
	12.12	Murine retrovirus integration site 1 (Mrvi1)*
	11.31	CD55 antigen (CD55)*
	4.29	N-myc downstream regulated gene 1 (Ndrg1)*
	3.48	Downstream of Tyrosine kinase 2 (Dok2)
	2.64	CCAAT enhancer binding protein, beta (Cebpb)
	2.46	A disintegrin and metalloprotease domain 8 (Adam8)
	2.46	Arrestin, beta 2 (Arrb2)
	2.40	Selectin, lymphocyte (Sell)
	2.30	Talin (Tln)
	2.30	Enolase 3, beta muscle (Eno3)
Suppressed Genes	3.03	Interleukin-15 (Il15)
	3.03	Neuronal pentraxin receptor (Nptxr)
	3.03	Ciliary neurotrophic factor (Cntf)
	2.64	Vimentin (Vmn)
	2.46	Suppression of tumorigenicity 7 (St7)
	2.30	Nuclear factor IX (Nfix)
	2.30	Growth arrest specific 5 (Gas5)
	2.14	Ribosomal protein S20 (Rps20)
B. Validation by Quantitative PCR
Gene Name	Mean Fold-Change	p -Value
Cd55	4.87 ± 1.31	0.02
Dok2	4.57 ± 1.82	0.07
Mrvi1	11.08 ± 0.76	0.0001
Ndrg1	4.92 ± 0.50	0.01

(A) Selected genes induced or suppressed by BCR-ABL by two-fold or more after 1 week of activation. Genes chosen for validation by Q-PCR are denoted by asterisks. (B) Q-PCR was performed in triplicate using RNA samples extracted from 2-4 distinct cell populations Mean fold-induction at 1 week compared to the expression at 0 h and standard error mean (SEM) are shown for each gene. A student t-test was performed to obtain P-values for the difference between the mean gene expression level at 0 h and 1 week. "I" and "S" denote "induced" and "suppressed", respectively
Although not selected for the validation study, Talin was previously reported to be induced in a BCR-ABL expressing cell line [31, 32].